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Abstract
Background:  Fibrin D-dimer levels have been advocated as an useful clinical marker of
thrombogenesis.
Hypothesis: We hypothesized that i) there is a hyperclotting state after the return of atrial
fibrillation to sinus rhythm, ii) the measurement of plasma D-Dimer levels might be a good
screening tool of this clotting status, and iii) the duration of arrhythmia influences the haemostasis
measured by plasma D-Dimer levels.
Methods: Forty-two patients with atrial fibrillation undergoing cardioversion were divided into
two groups: in Group A (n = 24,14 male, 56 ± 11 years) the duration of atrial fibrillation was 72
hours or more (142.7 ± 103.8 hours), in Group B (n = 18, 10 male, 61 ± 13 years) the duration of
atrial fibrillation was less than 72 hours (25 ± 16 hours). Plasma fibrin D-dimer levels were
measured by enzyme immunoassay before, and 36 hours after, cardioversion. The change of plasma
D-dimer levels 36 hours after cardioversion was calculated as delta-D-dimer.
Results: There were no significant differences in demographic, clinical, and echocardiographic
data, and the success of cardioversion between the two groups. Compared to the control, the
baseline D-dimer levels were significantly higher in both groups. The delta D-dimer levels were
significantly higher in Group A than in Group B (p < 0.005). Furthermore, plasma D-dimer levels
36 hours after cardioversion (r = 0.52, p = 0.0016) and delta-D-dimer levels (r = 0.73, p < 0.0001)
showed significant correlations with the duration of atrial fibrillation.
Conclusion: The longer duration of the atrial fibrillation episode could lead to a more prominent
cardiovascular hyperclotting state after cardioversion, and the mean changes of plasma D-Dimer
levels could be used as an useful clinical marker of the clotting state after atrial systole return.
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Introduction
Atrial fibrillation is the most common sustained arrhyth-
mia in clinical practice. It is associated with an increased
risk of thrombus formation, resulting in substantial mor-
bidity, with the augmented risk of stroke being the most
serious. This could be explained by haemostasis condi-
tions favouring thrombosis: previous studies have dem-
onstrated that in most patients, AF is a high risk factor for
hypercoagulability, irrespective of underlying structural
heart diseases or aetiology [1-8].
In addition, it is well known that the direct current cardi-
oversion of atrial fibrillation, especially if persisting >48
h, carries a great risk of thromboembolism, which extends
to 5% of cases not receiving anticoagulant therapy. The
mechanism and pathogenesis of thromboembolic epi-
sodes after restoration of sinus rhythm in these patients is
not completely understood.
There is some evidence that the prothrombotic state asso-
ciated with atrial fibrillation might contribute towards the
risk of thromboembolism following cardioversion, but
reports are not clear. In this context, having a marker of
coagulation activation would be useful in identifying
patients at highest thromboembolic risk. Indicators of
hypercoagulability, such as D-dimers, which are indica-
tive of a prothrombotic state, might also be indicative of
thromboembolic risk [9]. D-dimers, which originate from
the formation and lysis of cross-linked fibrin, are there-
fore specific markers of coagulation activation. In AF ele-
vated D-dimer levels have been reported to be associated
with left atrial appendage dysfunction [10], and the
potential presence of atrial thrombi. Anticoagulation does
reduce D-dimer levels, but there were no significant corre-
lations of D-dimer levels with either warfarin dose or the
INR [11,12]. D-dimer levels may also increase as a result
of comorbidity conditions causing intravascular (i.e. in
thrombosis) or extravascular cross-linked fibrin turnover,
such as in renal failure, liver impairment, acute or chronic
infection, neoplastic disease, hypertension, acute cardio-
vascular syndromes, bleeding, haematoma and surgery.
The interpretation of D-dimer levels can, therefore, be
considered as reflecting the prothrombogenic state of
patients without these acute clinical conditions, and with-
out overt thrombosis. [9] However, the age of the patient
must be considered: D-dimer levels are reported to
increase with age [13-15], which makes the interpretation
of D-dimer measurement very difficult and hazardous in
older people. Thus, before an evaluation of the predictive
role of D-dimer levels for thromboembolic events in AF
patients can be made, two conditions must be fulfilled: D-
dimer levels should be characteristic of each patient with
AF, and the presence of co-morbidity should be excluded.
We therefore hypothesized that i) there is still a hyperclot-
ting state after return of sinus rhythm, ii) the measure-
ment of plasma D-dimer levels pre- and post-
cardioversion might be a good screening tool of this clot-
ting status, and iii) the duration of arrhythmia could be a
good predictor of thromboembolic events after cardiover-
sion, due to the influence on haemostasis measured by
plasma D-dimer levels.
Table 1: Clinical Characteristics for Total Study Group
Group A (n = 24) Group B (n = 18) Control Group (n = 19)
Age (years) 56 ± 11 61 ± 13 59 ± 12
Male gender 14(58%) 10(56%) 10(57%)
Smokers 15(62.5%) 11(62%) 11(62.5%)
Systolic Blood Pressure (mmHg) 145 ± 20 143 ± 22 139 ± 25
Diastolic Blood Pressure (mmHg) 80 ± 10 82 ± 11 80 ± 11
Known hypertension (160/90 mmHg) 8 (33.4%) 6 (34%) 7(35%)
Lone AF 11(45.8%) 8 (44.2%) -
Coronary artery Disease 5(20.8%) 4(22%) 5(22.8%)
Diabetes mellitus 6(25%) 4(22%) 4(22.3%)
Hct(%) 45.8 ± 3.9 44.9 ± 4.2 45 ± 3.6
Hb(g/dl) 15.3 ± 1.34 14.8 ± 2.9 15.2 ± 3.1
Fbg (mg/dl) 229.9 ± 27.0 237 ± 37.6 227 ± 26
P value: non significant (NS)
Echocardiographic data for Both Groups pre cardioversion
Group A Group B
Left atrial diameter(cm) 4.2 ± 0.6 4.0 ± 0.8
Left ventricular diastolic dimension (cm) 5.2 ± 1.0 5.0 ± 0.9
Left ventricular systolic dimension (cm) 4.1 ± 0.5 4.0 ± 0.8
P value: non significant (NS)Thrombosis Journal 2005, 3:2 http://www.thrombosisjournal.com/content/3/1/2
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Methods
Over a period of 18 months, we studied 42 consecutive
patients, aged between 39–68 years old, with non-valvu-
lar atrial fibrillation who underwent successful electrical
cardioversion and who remained in sinus rhythm at the
one-month visit. Exclusion criteria were other acute causes
of atrial fibrillation (for example, thyrotoxicosis, pneu-
monia or other infections), acute cardiovascular or cere-
bro-vascular events (myocardial infarction, congestive
heart failure, stroke, etc) occurring within five months,
valvular heart disease, malignancy, connective tissue dis-
ease, infectious or inflammatory conditions and chronic
renal/hepatic disease. The patients were divided into two
groups. In Group A (24 pts, 14 male, 56 ± 11 years), the
duration of atrial fibrillation was 72 hours or more (142.7
± 103.8 hours). In Group B (18 pts, 10 male, 61 ± 13
years) the arrhythmia had a duration of less than 72 hours
(25 ± 16 hours). We included only patients treated with
anticoagulant-coumadin for chronic prophylaxis. There
was not a statistically significant difference between the
mean duration of anticoagulation treatment between the
two groups (14 ± 4 months for group A and 12 ± 6 months
for Group B). Prothrombin time to an INR (international
normalized ratio) of 2.5–3 was considered as a necessary
inclusion criterion for all patients. The total population
had a history of drug refractory atrial fibrillation, with a
serious number of arrhythmia episodes. We only analyzed
the documented arrhythmia episodes. The total number
of documented episodes of paroxysmal atrial fibrillation
in Group A was 33, and in Group B the patients had 36
confirmed arrhythmia episodes. There were no significant
differences in age, sex, hematocrit, hemoglobin, plasma
fibrinogen level, underlying heart disease, success ratio of
electrical cardioversion, echocardiographic data, presence
of diabetes mellitus or hypertension between the two
groups. The clinical characteristics of the patients are
shown in Table 1. AF was seen at the 12 lead surface elec-
trocardiogram. We compared the D-dimer levels of these
two groups at baseline, before cardioversion with a
matched control group (n = 19) without atrial fibrillation.
Plasma Fibrin D-dimer levels were measured before, and
36 hours after, cardioversion. Anticoagulation reduces D-
dimer levels, but as we analyzed the D-dimer levels of the
same patients pre- and post-cardioversion, we did not
need to use a cut-off value, and all patι ents were under
coumadin treatment with an INR (international normal-
ized ratio) of 2.5 to 3 at least 3 weeks before cardiover-
sion, and 36 hours post-cardioversion. The study protocol
was approved by the local ethics committee (Academic
Hospital of Alexandroupolis decision 09/11/2002). All
patients received oral and written information concerning
the background of the study, and signed informed
consent.
Laboratory
An intravenous line was placed and blood samples for D-
dimer measurement were taken from the patients imme-
diately before cardioversion, and 36 hours after recovery
of sinus rhythm. Citrated plasma was obtained from
venous blood by centrifugation at 2,500 rpm for 15 min
at 4°C. Aliquots were stored at -70°C to allow batch anal-
ysis. The plasma D-dimer levels were measured by the
enzyme-linked immunosorbent assay method. The meas-
urements were obtained with the use of a quantitative
sandwich immunochromatographic technique (Cardiac
D-Dimer; Roche Diagnostics, Mannheim, Germany). For
every blood sample, measurements were done twice. The
investigators and attending physicians were blinded to the
D-dimer test results. Inrta-assay coefficients of variation
for assays were <5%, inter-assay variances were 10%. The
changes of plasma D-dimer levels 36 hours after cardio-
version were calculated as delta- D-dimer.
Echocardiography
Echocardiographic examinations were performed in all
patients, immediately prior to the procedure and 36 hours
after successful cardioversion. Transthoracic echocardio-
graphic two-dimensional imaging and guided pulsed
wave Doppler recordings were obtained. Transmitral
Doppler inflow velocities were recorded from the apical
four-chamber view.
Peak velocities of early fillings (E) wave and atrial filling
(A) wave were determined. The inter- and intra-observer
variability was <5% for these measurements. We did not
detect the presence of thrombi in the left atrium. How-
ever, the absence of thrombus on transthoracic echocardi-
ography does not preclude the real absence of thrombus.
Statistical Analysis
Clinical variables are expressed as the mean value ± SD.
The effects of duration from the onset of atrial fibrillation
on the measured indexes were analyzed by two-way
repeated measures analysis of variance (ANOVA). Sequen-
tial data pre- and post-cardioversion were analyzed by
Friedman's repeated measures analysis of variance. Corre-
lations were performed by Spearman's rank correlation
method. Stepwise multiple regression analyses were per-
formed to determine independent predictors for plasma
D-dimer levels, using age, sex, left-atrial size, left ventricu-
lar dimensions (diastole, systole) presence of underlying
medical disease, smoking status, and the presence of atrial
fibrillation. A p value < 0.05 was considered statistically
significant. Analyses were performed with SAS for Win-
dows 8.02 (SAS Institute Inc., Cary, North Carolina) and
GraphPad Prism, version 3.00 (GraphPadSoftware, San
Diego, California) statistical software packages.Thrombosis Journal 2005, 3:2 http://www.thrombosisjournal.com/content/3/1/2
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Results
The baseline D-dimer levels of each group are shown in
Table 2. The D-dimer levels in the control group were sig-
nificantly lower than both groups (p < 0.05) (Table 2).
The patients' sinus rhythm was restored by applying elec-
trical cardioversion in all study patients. Delta D-dimer
levels were significantly higher in Group A than in Group
B. (p < 0.005).
There were no significant differences in plasma D-dimer
levels before, and 36 hours after, cardioversion between
the two Groups (Table 3). Furthermore, plasma D-dimer
levels 36 hours after cardioversion, and delta D-dimer lev-
els showed significant correlations with the duration of
atrial fibrillaton: D-dimer 36 hours after CV; r = 0.52, p =
0.0016, delta D-dimer; r = 0.73, p < 0.0001.
The echocardiographic data 36 hours after CV have
changed. There was a return of atrial contractility using
Doppler echocardiography, as shown by the progressive
increase in A-wave velocity (Friedman's repeated meas-
ures ANOVA, p < 0.0001).
Two embolic stroke events were recorded during the six
hours after cardioversion in Group A (8,33%) and none in
Group B. The embolic events occurred in two women with
an INR of 2.6 and 2.9 respectively. At the onset of the
event one patient had D-dimer levels of 112.2 ng/ml
while the second patient had D-dimer levels of 109.8 ng/
ml. Fortunately, these were transient events. The compu-
terized tomography detected non-extentend thromboem-
bolic areas.
Discussion
In the present study we analyzed D-dimer levels as a
screening index of a hyperclotting state after cardioversion
of atrial fibrillation. It would be more useful if we used the
term abnormal haemostasis, because the fibrin D-dimer is
a cross-linked degradation product, resulting from the
balance between thrombogenesis and the fibrinolysis
process.
Fibrin D-dimer levels have been established as a useful
clinical marker of thrombogenesis. [16] The use of D-
Dimer levels in the investigation and management path-
way of venous thromboembolism is well established. [17]
This marker has a high sensitivity and specificity in
excluding thromboembolism, when a well-defined assay
is used in the appropriate clinical setting. [18]
In "normal" patients, elevated D-dimer levels have been
associated with a higher risk of developing cardiovascular
disease. [19] Also, such cross-linked fibrin degradation
products have been shown to be strong and independent
predictors of the severity of occlusive peripheral artery dis-
ease [20].
Patients with long-lasting episodes of atrial fibrillation or
chronic atrial fibrillation are characterized by increased
levels of plasma D-dimers [21,22], platelet activation, and
endothelial damage and/or dysfunction, which is consist-
Table 2: Mean D-Dimer levels at baseline before cardioversion in both groups and the relationship with he control group
Group A Group B p value
Mean D-Dimer 117 ± 74.7 ng/ml 102 ± 53.8 NS
Group A Control Group p value
Mean D-Dimer 117 ± 74.7 ng/ml 39.7 ± 28.6 0.05
Group B Control Group p value
Mean D-Dimer 102 ± 53.8 39.7 ± 28.6 0.05
Table 3: D-dimer levels (ng/ml) in both Groups of Patients
D-dimer before CV D-dimer after CV delta D-dimer
Group A 117.9 ± 74.7 ng/ml 104.1 ± 59.7 ng/ml 34.2 ± 63.6 ng/ml°
Group B 102 ± 53.8 ng/ml 84.7 ± 78. 2 ng/ml -17.3 ± 37.8 ng/ml
Values are expressed as mean ± SD, °p = 0.005 vs Group B.Thrombosis Journal 2005, 3:2 http://www.thrombosisjournal.com/content/3/1/2
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ent with the increased predisposition to thrombus forma-
tion in this group of patients [23]. Some investigators
have shown that the cardioversion of atrial fibrillation to
sinus rhythm results in a decrease of D-dimer levels [24].
Our data showed elevated D-dimer levels in individuals
who received appropriate anticoagulation therapy at the
time of cardioversion. This may suggest the presence of
some remaining clot. But we could not estimate this
hypothesis because we did not have the profile of D-dimer
levels of all patients during a long period before the time
of enrolment.
In the present study, the plasma D-dimer levels decreased
in both groups after successful cardioversion, but the
mean change in D-dimer levels pre- and post- cardiover-
sion was significantly lower in Group A than in Group B,
and D-dimer levels continued to be high, even 36 hours
after the procedure in Group A. There were reported
embolic events in 8.33% of Group A patients, with the
higher delta D-dimer.
These data confirm the existence of an abnormal clotting
state after the cardioversion of atrial fibrillation, which
could be the cause of the thromboembolic events
observed after the return to sinus rhythm, even under
anticoagulation.
The mechanism of thromboembolism is debatable. The
results we found could suggest an embolism might be
caused by detachment of a formed thrombus during the
phase of passage from AF to sinus rhythm, due to being
heavily compromised by stunning the mechanical func-
tion of the left atrium and left atrium appendage after
sinus rhythm restoration. The stunning of the left atrium
and left atrium appendage might attenuate the thrombo-
genetic activation which our result showed.
In the present study we also provided evidence that this
hypercoaguable state after successful cardioversion of
atrial fibrillation related directly to the duration of the
arrhythmia episode. It has been accepted that chronic
atrial fibrillation is characterized by increased levels of
plasmatic D-dimers, with a wide inter-individual variabil-
ity, depending on the patients and therapeutic character-
istics. However, it has not been established if this level
could also be characteristic of paroxysmal or persistent
atrial fibrillation in patients, and whether it could be a
predictive factor for the risk of thromboembolic events
after cardioversion to sinus rhythm.
Our results show that longer duration of atrial fibrillation
could lead to a more prominent cardiovascular hyperclot-
ting state after cardioversion and that the duration of the
arrhythmia episode might be a risk factor for the high inci-
dence of post-cardioversion thromboembolic events.
Importantly, this hypercoaguable state does not appear to
be subject to any other clinical variables, nor is it related
to whether or not the patient had a lone atrial fibrillation
or not, suggesting that the duration of the arrhythmia epi-
sode confers a constant prothrombotic state per se, after
cardioversion to sinus rhythm, which was independent of
the etiology but dependent on the duration of the arrhyth-
mia. Interestingly enough, this hyperclotting state after
cardioversion exists even under appropriate anticoagu-
lative treatment. The relation of the markers of accelerated
coagulation to clinical or echocardiographic risk factors
for thromboembolism is controversial.
Our results clearly demonstrate a positive correlation of
the based on the arrhythmia duration clinically predicted
embolic risk to the mean change of plasma D-dimer levels
36 hours after successful cardioversion. We could not
detect any relation to the echocardiographic risk factors,
probably due to our inability to perform a transesopha-
geal echocardiography. The present study suggests that
even in the absence of clinical conditions causing
increased embolic risk, patients with signs of accelerated
coagulation are at risk of thrombus formation in the
future.
In conclusion, a longer duration of the atrial fibrillation
episode could lead to a more prominent cardiovascular
hyperclotting state after cardioversion, and the mean
changes of plasma D-Dimer levels could be used as an
useful clinical marker of the clotting state after atrial sys-
tole return.
Clinical implications
Our study might have practical implications for the man-
agement of patients with an episode of atrial fibrillation,
regardless of the anticoagulative treatment they are receiv-
ing: the episode must be terminated as soon as possible,
because the pathogenesis of thrombus formation in atrial
fibrillation is very complex and not yet completely
defined. Further investigations with a large population are
needed to define all the pathophysiologic mechanisms of
thrombus formation.
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